Latest Kaiser Health News Stories
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
An expert geriatrician says the benefits for the patient, such as alleviating pain and maintaining independence, must be weighed against the possible risks. Her motto: ‘start low and go slow.’
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
African-American women are more likely to be infected with HIV than other women. So the District of Columbia is launching an effort to inform them about PrEP, medication that can reduce their risk.
The designation, which is made by the Food and Drug Administration, allows drugmakers to claim seven years of market exclusivity.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
Follow the twists and turns of the orphan drug industry over the past three decades.
Eight percent of those polled by the Kaiser Family Foundation say they have purchased medications outside of the U.S. to save money.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.
Despite heavy opposition from the pharmaceutical industry and skepticism from policy experts, many voters see Proposition 61 as a way to protest the nation’s mounting drug prices.
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
KHN’s Julie Appleby joined forces with USA Today to create this chart, which details the various industry players and how they contribute to a prescription drug’s cost.
Two prescription medications have been found to be successful in helping many patients with alcohol cravings. Yet they are rarely used and many patients don’t know they exist.
Ten-year-old Josh Hardy died last month. His struggle to survive helped to spur laws to get unapproved drugs to the terminally ill.